

CARD protocol

A 'practice changing' trial


mCRPC
 progressing (≤ 12
months) on ABI or
 ENZA) before or after
 Docetaxel

n=324

Stratification factors: ECOG (0-1 vs 2), **time to progression** (≤ 6 vs 6-12 mths), timing of AR-targeted agent (before or after docetaxel)

Countries: Europe

Sponsor: Sanofi



Primary endpoint: radiological PFS

Secondary end-points: PSA response, ECOG, PFS (clinical or radiological), objective tumor response, pain, (QoL), time to SREs, OS, safety, biomarkers